S
Sandeep Tyagi
Researcher at Johns Hopkins University
Publications - 40
Citations - 2883
Sandeep Tyagi is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Mycobacterium tuberculosis & Pyrazinamide. The author has an hindex of 25, co-authored 37 publications receiving 2676 citations. Previous affiliations of Sandeep Tyagi include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Eric L. Nuermberger,Tetsuyuki Yoshimatsu,Sandeep Tyagi,Richard J. O'Brien,Andrew N. Vernon,Richard E. Chaisson,William R. Bishai,Jacques H. Grosset +7 more
TL;DR: Using a murine model that is representative of chemotherapy for human tuberculosis, the combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycobacterium tuberculosis from the lungs of infected mice by up to 2 months when compared with the standard regimen.
Journal ArticleDOI
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative σ factor, SigH
Deepak Kaushal,Benjamin G. Schroeder,Sandeep Tyagi,Tetsuyuki Yoshimatsu,Cherise P. Scott,Chiew Ko,Liane Carpenter,Jyoti Mehrotra,Yukari C. Manabe,Robert D. Fleischmann,William R. Bishai +10 more
TL;DR: Data show that the M. tuberculosis sigH gene is dispensable for bacterial growth and survival within the host, but is required for the production of immunopathology and lethality.
Journal ArticleDOI
Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis
Eric L. Nuermberger,Tetsuyuki Yoshimatsu,Sandeep Tyagi,Kathy N. Williams,Ian M. Rosenthal,Richard J. O'Brien,Andrew Vernon,Richard E. Chaisson,William R. Bishai,Jacques H. Grosset +9 more
TL;DR: The use of rifampin, moxifloxacin, and pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis and that the full benefit of pyraz inamide in this regimen may be realized after just 1 month of treatment.
Journal ArticleDOI
Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis
Sandeep Tyagi,Eric L. Nuermberger,Tetsuyuki Yoshimatsu,Kathy N. Williams,Ian M. Rosenthal,N Lounis,William R. Bishai,Jacques H. Grosset +7 more
TL;DR: Encouraging data strongly support further evaluation of PA-824 in combination with first- or second-line antituberculosis drugs to determine its potential contribution to the treatment of drug-susceptible or multidrug-resistant tuberculosis, respectively.
Journal ArticleDOI
Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
Eric L. Nuermberger,Sandeep Tyagi,Rokeya Tasneen,Kathy N. Williams,Deepak V. Almeida,Ian M. Rosenthal,Jacques H. Grosset +6 more
TL;DR: It is reported that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and fireworks.